12 Month Price Forecast For PIII
Distance to PIII Price Forecasts
PIII Price Momentum
🤔 Considering P3 Health Partners (PIII)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 23, 2025 12:16 PM UTC
PIII Analyst Ratings & Price Targets
Based on our analysis of 4 Wall Street analysts, PIII has a consensus that is neutral. The median price target is $0.63, with forecasts ranging from $0.25 to $1.00. Currently, there are 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
With PIII currently trading at $0.19, the median price forecast suggests a 221.7% upside. The most optimistic forecast comes from at , projecting a 414.7% upside, while Gary Taylor at TD Cowen provides the most conservative target, suggesting a 28.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PIII Analyst Consensus
PIII Price Target Range
Latest PIII Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PIII.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 20, 2024 | TD Cowen | Gary Taylor | Hold | Maintains | $0.25 |
| Apr 1, 2024 | BTIG | David Larsen | Neutral | Downgrade | $0.00 |
| Mar 14, 2024 | Lake Street | Brooks O'Neil | Buy | Maintains | $4.50 |
| Sep 1, 2023 | BTIG | David Larsen | Buy | Initiates | $5.00 |
| Jun 30, 2023 | TD Cowen | Gary Taylor | Market Perform | Initiates | $0.00 |
| Jan 4, 2022 | William Blair | Ryan Daniels | Outperform | Initiates | $0.00 |
Stocks Similar to P3 Health Partners Inc.
The following stocks are similar to P3 Health Partners based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
P3 Health Partners Inc. (PIII) Financial Data
P3 Health Partners Inc. has a market capitalization of $128.41M with a P/E ratio of -0.3x. The company generates $1.40B in trailing twelve-month revenue with a -5.0% profit margin.
Revenue growth is +15.2% quarter-over-quarter, while maintaining an operating margin of -8.3% and return on equity of -41.2%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
P3 Health Partners Inc. (PIII) Company Overview
About P3 Health Partners Inc.
Provides population health management services.
The company operates clinics and wellness centers, focusing on patient-centered care led by physicians. It generates revenue by offering healthcare services that improve patient outcomes and manage population health effectively.
Founded in 2020 and based in Henderson, Nevada, P3 Health Partners Inc. aims to enhance healthcare delivery in the United States.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
400
CEO
Dr. Aric Coffman M.D.
Country
United States
IPO Year
2021
Website
p3hp.orgP3 Health Partners Inc. (PIII) Latest News & Analysis
P3 Health Partners Inc. (NASDAQ: PIII) will present at the J.P. Morgan Healthcare Conference on January 14, 2024, at 7:30 AM PT. A webcast will be available on their Investor Relations website.
P3 Health Partners' participation in a major healthcare conference highlights its visibility and potential for growth in the healthcare sector, which may influence investor sentiment and stock performance.
Kuehn Law is investigating P3 Health Partners Inc. (NASDAQ: PIII) for possible fiduciary duty breaches by its officers and directors related to potential self-dealing.
The investigation into P3 Health Partners' officers for potential self-dealing may signal governance issues, impacting investor confidence and possibly affecting stock performance.
P3 Health Partners to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference
1 month agoP3 Health Partners Inc. (NASDAQ: PIII) will present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference on December 3, 2024. A webcast will be available on their Investor Relations site.
P3 Health Partners' upcoming presentation at a prominent investment conference highlights its growth potential and offers insights into its strategy, influencing investor interest and market perception.
P3 Health Partners Inc. (NASDAQ: PIII) will participate in the Needham Virtual Healthcare IT Conference on November 20, 2024, and the BTIG Digital Health Forum on November 25, 2024.
P3 Health Partners' participation in key investor conferences signals increased visibility and potential investor interest, which could impact stock performance and market perception.
P3 Health Partners Inc. (NASDAQ: PIII) will hold its Q3 2024 earnings call on November 12, 2024, at 4:30 PM ET, featuring key executives and analysts from various firms.
P3 Health Partners' Q3 earnings call offers insights into financial performance and strategic direction, impacting stock valuation and investor sentiment.
P3 Health Partners Inc. (NASDAQ: PIII) reported its Q3 financial results for 2024, emphasizing strategic initiatives aimed at achieving sustainable, profitable growth.
P3 Health Partners' Q3 financial results indicate potential for sustainable growth, signaling to investors an opportunity for value appreciation in the company's stock.
Frequently Asked Questions About PIII Stock
What is P3 Health Partners Inc.'s (PIII) stock forecast for 2025?
Based on our analysis of 4 Wall Street analysts, P3 Health Partners Inc. (PIII) has a median price target of $0.63. The highest price target is $1.00 and the lowest is $0.25.
Is PIII stock a good investment in 2025?
According to current analyst ratings, PIII has 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.19. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for PIII stock?
Wall Street analysts predict PIII stock could reach $0.63 in the next 12 months. This represents a 221.7% increase from the current price of $0.19. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is P3 Health Partners Inc.'s business model?
The company operates clinics and wellness centers, focusing on patient-centered care led by physicians. It generates revenue by offering healthcare services that improve patient outcomes and manage population health effectively.
What is the highest forecasted price for PIII P3 Health Partners Inc.?
The highest price target for PIII is $1.00 from at , which represents a 414.7% increase from the current price of $0.19.
What is the lowest forecasted price for PIII P3 Health Partners Inc.?
The lowest price target for PIII is $0.25 from Gary Taylor at TD Cowen, which represents a 28.7% increase from the current price of $0.19.
What is the overall PIII consensus from analysts for P3 Health Partners Inc.?
The overall analyst consensus for PIII is neutral. Out of 4 Wall Street analysts, 2 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $0.63.
How accurate are PIII stock price projections?
Stock price projections, including those for P3 Health Partners Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
